search
Back to results

Non-invasive Stimulation in Neurofibromatosis Type 1 (tDCS is NF1)

Primary Purpose

Neurofibromatosis 1

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Transcranial direct current stimulation
Sponsored by
University of Manchester
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Neurofibromatosis 1 focused on measuring working memory

Eligibility Criteria

11 Years - 16 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. children aged 11-16 years
  2. With a confirmed diagnosis (wither clinical or genetic) of Neurofibromatosis Type 1
  3. Informed consent/assent

Exclusion Criteria:

  1. Child on active treatment for any NF1 related complications (such as chemotherapy for optic glioma)
  2. Children with a known history of Epilepsy or on anti-epileptic medication
  3. Children with poor verbal communication
  4. Children with cardiac pacemakers, joint replacements or metal implants will be excluded.
  5. Children with any previous operations to their head will be excluded.

Sites / Locations

  • University of Manchester

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

tDCS Active arm

tDCS Sham arm

Arm Description

The experimental arm will have the tDCS stimulation electrodes placed on the scalp and the current will be delivered over 20 minutes

The sham arm will have electrodes placed over the scalp and will be given the current for 10 seconds after which it will be ramped down and stopped.

Outcomes

Primary Outcome Measures

n-back test
visuo-spatial and auditory n-back test to assess working memory

Secondary Outcome Measures

Full Information

First Posted
October 10, 2017
Last Updated
April 22, 2019
Sponsor
University of Manchester
search

1. Study Identification

Unique Protocol Identification Number
NCT03310996
Brief Title
Non-invasive Stimulation in Neurofibromatosis Type 1
Acronym
tDCS is NF1
Official Title
Use of Non-invasive Brain Stimulation for Working Memory Deficits in Neurofibromatosis Type 1
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
October 13, 2017 (Actual)
Primary Completion Date
June 30, 2018 (Actual)
Study Completion Date
June 30, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Manchester

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Intellectual impairments are a significant cause of morbidity in children with birth defects along with long term implication on academic and occupational functioning. Long lasting functional changes in the brain occur when children learn new things or memorise new information. Enhancing this and learning is a key objective inneurodevelopment and neuro-rehabilitation. This is pilot study aimed at testing a experimental neuroscience technique, Transcranial Direct Current Stimulation (tCDS) on the cognitive functioning of the brain in children with Neurofibromatosis type 1 (NF1). tDCS is an established research tool and has the potential for ameliorating the cognitive impairments associated with NF1. There is a growing interest in the use of tDCS in children but to our knowledge there have been no reported studies using tDCS intervention in NF1. 16 children aged 11-16 years will be recruited through the Manchester Centre of Genomic Medicine NF1 database. Participants will be randomised to receive active or sham tDCS. The treatment will be delivered for 20 minutes for 3 days. In the experimental group a 1mA current will be applied for 20 mins ; in sham tDCS the electrodes will be placed in an identical spot but the current is ramped down to 30 seconds to prevent stimulation. The aim of the study is to look into the acceptability and feasibility of using tDCS intervention within the NF1 group, obtain pilot data on the effect of tDCS on EEG (Electroencephalogram), cognitive and behavioural measures.
Detailed Description
16 children between the age of 11-16 years will be recruited through Manchester Centre of Genomic Medicine NF1 Database. The participants will be randomly assigned to 2 groups- active and sham treatment based on a computer generated random allocation list. The assessors will remain blind to treatment allocation. On day 1, parents will be requested to complete well validated and standardised questionnaires. Baseline recording of the brain activity EEG(Electroencephalogram) will be measured and the baseline cognitive assessments will be completed on the participants. tCDS will be administered for 20 minutes alongside a simultaneous training task for working memory. Days 2, the tDCS (active or sham) will be delivered simultaneous with the training task for 20 minutes. On day 3, the tDCS intervention will be delivered followed by repeating the outcome measures similar to day 1. A questionnaire investigating side-effects be will be completed by participant after each stimulation.Participants will be invited back to the lab 30 days (+/- 7 days) after the end of intervention to assess the longevity of any treatment effects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neurofibromatosis 1
Keywords
working memory

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
NeuroConn DC-STIMULATOR PLUS (NeurConn, GmbH), model number: 0021; serial number: 0351
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
Both sham and active treatment arms will have electrodes places on the scalp. The sham arm will have the current turned off in 10 seconds.
Allocation
Randomized
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Arm Title
tDCS Active arm
Arm Type
Experimental
Arm Description
The experimental arm will have the tDCS stimulation electrodes placed on the scalp and the current will be delivered over 20 minutes
Arm Title
tDCS Sham arm
Arm Type
Placebo Comparator
Arm Description
The sham arm will have electrodes placed over the scalp and will be given the current for 10 seconds after which it will be ramped down and stopped.
Intervention Type
Other
Intervention Name(s)
Transcranial direct current stimulation
Other Intervention Name(s)
Non-invasive brain stimulation
Intervention Description
tDCS is an established research tool for non-invasive modulation of neuroplasticity. It has shown promise as a neurorehabilitation tool and demonstrated positive effects in various clinical conditions such as Alzheimer's, stroke, childhood psychosis, epilepsy and dystonias. tDCS uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential.
Primary Outcome Measure Information:
Title
n-back test
Description
visuo-spatial and auditory n-back test to assess working memory
Time Frame
Day 3 of intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
11 Years
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: children aged 11-16 years With a confirmed diagnosis (wither clinical or genetic) of Neurofibromatosis Type 1 Informed consent/assent Exclusion Criteria: Child on active treatment for any NF1 related complications (such as chemotherapy for optic glioma) Children with a known history of Epilepsy or on anti-epileptic medication Children with poor verbal communication Children with cardiac pacemakers, joint replacements or metal implants will be excluded. Children with any previous operations to their head will be excluded.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shruti Garg, MRCPsych, PhD
Organizational Affiliation
University of Manchester
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Manchester
City
Manchester
State/Province
Greater Manchester
ZIP/Postal Code
M13 9QQ
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
We plan to make the data available to other researchers upon request once the study has been completed.

Learn more about this trial

Non-invasive Stimulation in Neurofibromatosis Type 1

We'll reach out to this number within 24 hrs